权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Towards an inclusive genomic risk classification for acute myeloid leukemia (AML)

迈向急性髓系白血病 (AML) 的包容性基因组风险分类

基本信息

批准号：
10752188
负责人：
Ann-Kathrin Eisfeld
金额：
$ 68.74万
依托单位：
OHIO STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-09-18 至 2028-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10752188
关键词：
Acute Myelocytic Leukemia Acute leukemia Adult Affect African ancestry Algorithms American Architecture Archives Assessment tool Biological Biological Assay Biological Testing Biology Cell surface Cells Classification Clinical Clinical Pathways Clonality Cytogenetics DNA Resequencing Data Disease European European ancestry Exhibits FLT3 gene Frequencies Gene Mutation Genes Genetic Genetic Risk Genetic Transcription Genetically Engineered Mouse Genome Genomics Genotype Goals Human Human Genetics Incidence Knowledge Malignant Neoplasms Medical Genetics Modality Modeling Molecular Mutate Mutation Oncogenic Open Reading Frames Outcome Patients Population Prediction of Response to Therapy Prognosis Prognostic Marker Publications Publishing RNA Splicing RNA analysis Recurrence Relapse Residual Neoplasm Resistance Risk Risk Adjustment Role Sampling Somatic Mutation Testing Therapeutic Variant XCL1 gene Xenograft Model Xenograft procedure acute myeloid leukemia cell cancer genetics chemotherapy clinical practice clinical risk cohort driver mutation drug development exome exome sequencing genetic panel test genetic risk assessment in vivo in vivo evaluation leukemia leukemic stem cell leukemogenesis multimodality multiple omics mutant novel precision oncology prognostic prognostic significance response risk stratification therapy development tool transcriptome sequencing treatment response treatment stratification tumor progression

项目摘要

A. PROJECT SUMMARY Acute myeloid leukemia (AML) is the most common adult acute leukemia. Molecular features such as cytogenetics and somatic mutations are essential components of risk stratification; used in daily clinical practice to determine treatment modality and intensity. Our knowledge of recurrent genetic AML-associated features, survival associations, subsequent genetic risk classification and clinical practice is informed by large- scale genomic studies performed over the past decade on patients of Central-European ancestry. Thus, current clinical practice is predicated on the supposition that adequate testing has been performed, and that genetic background should not affect the known AML-associated genetic and genomic landscape and genes that associate with treatment response and/or that drive AML-genesis. However, our published and preliminary data reveal that ancestry affects not only the frequencies and impact of known AML-associated gene mutations, but also multiple recurrent variants in genes thus-far not implicated in AML-genesis. We hypothesize that: a) known AML-associated drivers may carry different prognostic significance and might need to be adjusted in clinical risk classifications depending on ancestry, and b) some unrecognized molecular features are ancestry-associated drivers of AML-genesis and/or therapy resistance. We propose to extend our initial studies of AML genomes and genomics to provide statistical confidence around frequently mutated genes, and a more inclusive molecularly-adjusted risk and treatment stratification for AML patients. Next, we will focus on NPM1c, a genotype which confers favorable outcome in AML patients with Central-European ancestry, but poor outcomes in other ancestries. We will use cutting-edge single-cell multiomic assays to delineate bystander clonal mutations from potential driver mutations, then we will biologically test their role in clonality/leukemia-stem-cell frequency and treatment response. We expect to provide an inclusive characterization of the genetic and genomic landscape of AML, identify those variants with prognostic significance, and provide exemplars of here-to-fore unrecognized drivers of treatment response and survival. The overall goal is to enable precision oncology approaches which accommodate the effects of underlying human genetics.

A.项目总结